Compare IFBD & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFBD | BRTX |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Managed Health Care |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.3M |
| IPO Year | 2020 | 2015 |
| Metric | IFBD | BRTX |
|---|---|---|
| Price | $1.01 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 163.4K | ★ 25.4M |
| Earning Date | 05-01-2023 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.16 |
| 52 Week High | $2.18 | $1.89 |
| Indicator | IFBD | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 58.72 |
| Support Level | $0.88 | $0.20 |
| Resistance Level | $1.13 | $1.20 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 12.82 | 78.45 |
Infobird Co Ltd is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. The Company provides standard and customized customer relationship management cloud-based services, including SaaS and business process outsourcing (BPO) services. It generates revenue from the development and sale of software licenses for customized software, as well as from business integration solution services and digital advertising and marketing campaign services. Digital advertising revenue is generated from developing and executing advertising plans based on customer needs, and the Company generally provides limited warranties for work performed under its business integration solution contracts. The Company generates maximum revenue from its operations in Mainland China.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.